ANI Pharmaceuticals, Inc. (ANIP) |
| 81.68 0.03 (0.04%) 06-12 16:00 |
| Open: | 80.9716 |
| High: | 83.6598 |
| Low: | 80.75 |
| Volume: | 178,934 |
| Market Cap: | 1,857(M) |
| PE Ratio: | 20.89 |
| Exchange: | NASDAQ Global Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 102.50 |
| Resistance 1: | 87.76 |
| Pivot price: | 79.93 |
| Support 1: | 78.97 |
| Support 2: | 73.54 |
| 52w High: | 99.5 |
| 52w Low: | 61.18 |
ANI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, concentrating on the development, production, and commercialization of both proprietary (branded) and unbranded (generic) prescription medications across the United States and Canada. The company's primary focus areas include manufacturing controlled substances, treatments for oncology, hormones and steroids, injectable drugs, and various other pharmaceutical preparations. Its robust manufacturing capabilities encompass a range of dosage forms, such as oral solid products, semi-solids, liquid formulations, and topical agents, as well as highly potent compounds. Furthermore, ANI Pharmaceuticals provides contract development and manufacturing services to other pharmaceutical enterprises. The company distributes its products through a diverse network, which includes retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, and group purchasing organizations. Incorporated in 2001, its corporate headquarters are situated in Baudette, Minnesota.
| EPS | 3.910 |
| Book Value | 26.340 |
| PEG Ratio | 0.00 |
| Gross Profit | 24.718 |
| Profit Margin (%) | 9.98 |
| Operating Margin (%) | 16.30 |
| Return on Assets (ttm) | 5.0 |
| Return on Equity (ttm) | 18.3 |
Thu, 11 Jun 2026
Insider Sell: Thomas Haughey Sells 2,000 Shares of ANI Pharmaceu - GuruFocus
Wed, 10 Jun 2026
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock - Investing.com
Wed, 10 Jun 2026
ANI Pharmaceuticals (ANIP) director receives 4,357-share restricted stock award - Stock Titan
Wed, 10 Jun 2026
ANI Pharmaceuticals (ANIP) director sells 2,000 shares under plan - Stock Titan
Wed, 10 Jun 2026
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027 - Stock Titan
Wed, 10 Jun 2026
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - Yahoo Finance Singapore
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |